Intensive graft-versus-host disease prophylaxis is required after unrelated-donor nonmyeloablative stem cell transplantation (Q46375783)

21 December 2017

title

Intensive graft-versus-host disease prophylaxis is required after unrelated-donor nonmyeloablative stem cell transplantation (English)

1 reference

21 December 2017

13

D L Porter

1 reference

21 December 2017

Edward A. Stadtmauer

3

object named as

E A Stadtmauer

1 reference

21 December 2017

Alison Wakoff Loren

1

object named as

A W Loren

1 reference

21 December 2017

Selina Luger

2

object named as

S M Luger

1 reference

21 December 2017

author name string

D E Tsai

4

1 reference

21 December 2017

S Schuster

5

1 reference

21 December 2017

S D Nasta

6

1 reference

21 December 2017

S C Goldstein

7

1 reference

21 December 2017

A Perl

8

1 reference

21 December 2017

G Orloff

9

1 reference

21 December 2017

J C Oliver

10

1 reference

21 December 2017

J Green

11

1 reference

21 December 2017

S G Emerson

12

1 reference

21 December 2017

language of work or name

English

0 references

publication date

1 May 2005

1 reference

21 December 2017

Bone Marrow Transplantation

published in

1 reference

21 December 2017

volume

35

1 reference

21 December 2017

issue

9

1 reference

21 December 2017

page(s)

921-926

1 reference

21 December 2017

https://scigraph.springernature.com/pub.10.1038/sj.bmt.1704887

exact match

0 references

cites work

Evidence of a graft-versus-leukemia effect in chronic lymphocytic leukemia after reduced-intensity conditioning and allogeneic stem-cell transplantation: the Cooperative German Transplant Study Group.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704887

Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704887

Nonablative allogeneic hematopoietic transplantation as adoptive immunotherapy for indolent lymphoma: low incidence of toxicity, acute graft-versus-host disease, and treatment-related mortality

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704887

Allogeneic bone marrow transplant or second autograft in patients with acute leukemia who relapse after an autograft. Acute Leukaemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704887

Melphalan and purine analog-containing preparative regimens: reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704887

Characterization of the CAMPATH-1 (CDw52) antigen: biochemical analysis and cDNA cloning reveal an unusually small peptide backbone

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704887

Campath-1H monoclonal antibody therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704887

Limiting transplantation-related mortality following unrelated donor stem cell transplantation by using a nonmyeloablative conditioning regimen

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704887

Nonmyeloablative transplantation with or without alemtuzumab: comparison between 2 prospective studies in patients with lymphoproliferative disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704887

Feasibility of reduced intensity hematopoietic stem cell transplantation from an HLA-matched unrelated donor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704887

HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative conditioning for patients with hematologic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704887

Reduced-intensity allogeneic hematopoietic stem cell transplantation for myelodysplastic syndrome and acute myeloid leukemia with multilineage dysplasia using fludarabine, busulphan, and alemtuzumab (FBC) conditioning

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704887

BEAM-alemtuzumab reduced-intensity allogeneic stem cell transplantation for lymphoproliferative diseases: GVHD, toxicity, and survival in 65 patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704887

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704887

Differential CD52 expression by distinct myeloid dendritic cell subsets: implications for alemtuzumab activity at the level of antigen presentation in allogeneic graft-host interactions in transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704887

Persistence of host dendritic cells after transplantation is associated with graft-versus-host disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704887

Antileukemic effect of chronic graft-versus-host disease: contribution to improved survival after allogeneic marrow transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704887

7 January 2021

The graft-versus-leukaemia effect in haematopoietic stem cell transplantation using unrelated donors

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704887

7 January 2021

Transplant-lite: induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704887

7 January 2021

Role of Nonmyeloablative Allogeneic Stem-Cell Transplantation After Failure of Autologous Transplantation in Patients With Lymphoproliferative Malignancies

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704887

7 January 2021

Results of allogeneic bone marrow transplants for leukemia using donors other than HLA-identical siblings

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704887

7 January 2021

Efficient complement-mediated lysis of cells containing the CAMPATH-1 (CDw52) antigen

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704887

7 January 2021

Prevention of graft versus host disease by inactivation of host antigen-presenting cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704887

7 January 2021

Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704887

7 January 2021

Multiplex sets for the amplification of polymorphic short tandem repeat loci--silver stain and fluorescence detection

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704887

7 January 2021

Sequential molecular monitoring of chimerism in chronic myeloid leukemia patients receiving donor lymphocyte transfusion for relapse after bone marrow transplantation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704887

7 January 2021

Reduced-intensity conditioning for unrelated donor hematopoietic stem cell transplantation as treatment for myeloid malignancies in patients older than 55 years

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704887

7 January 2021

Campath-1G causes rapid depletion of circulating host dendritic cells (DCs) before allogeneic transplantation but does not delay donor DC reconstitution

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704887

7 January 2021

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704887

1 reference

7 January 2021

Major-histocompatibility-complex class I alleles and antigens in hematopoietic-cell transplantation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704887

7 January 2021

HLA matching for bone marrow transplantation--how much is enough?

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704887

7 January 2021

Identifiers

DOI

10.1038/SJ.BMT.1704887

1 reference

21 December 2017

1 reference

21 December 2017